-

Aptar to Host Virtual Capital Markets Day

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, will host a virtual Capital Markets Day on Friday, September 10, 2021. The event will begin at 9:00 a.m. EDT. Senior executives from the company will speak and then answer questions from the audience. Interested parties can access the presentation slides and listen live by visiting the Investor Relations page at www.aptar.com. A replay of this event will be available on the website for a minimum of 30 days.

About Aptar

Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Contacts

Investor Relations Contact:
Matt DellaMaria
matt.dellamaria@aptar.com
815-479-5530

Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671

AptarGroup, Inc.

NYSE:ATR

Release Versions

Contacts

Investor Relations Contact:
Matt DellaMaria
matt.dellamaria@aptar.com
815-479-5530

Media Contact:
Katie Reardon
katie.reardon@aptar.com
815-479-5671

More News From AptarGroup, Inc.

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhyt...

Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year...

Aptar Acquires Sommaplast, a Specialized Provider of Oral Dosing Pharma Packaging Solutions

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Acquires Sommaplast, a Specialized Provider of Oral Dosing Pharma Packaging Solutions...
Back to Newsroom